Magnum Ice Cream Co., spun out of Unilever last year, posted first‑quarter revenue of €1.7 billion, a 1% decline driven by adverse FX. Despite the dip, the group kept its organic growth target of 3‑5% for the year. Investors welcomed the results, lifting the stock 3.4% in early Amsterdam trading.

Consumer trends toward bite‑size and portion‑control formats helped offset softness in legacy lines such as Ben & Jerry’s. Organic sales rose 4.5% in Q1, beating analysts’ 2.6% forecast, while new launches – Magnum and Solero Bon Bons and Yasso frozen Greek yoghurt – delivered higher‑protein, lower‑calorie options aimed at diet‑conscious shoppers.

Unilever, still a major shareholder, reported stronger‑than‑expected personal‑care sales and reaffirmed its 4‑6% full‑year underlying growth outlook. The British group continues to prune lower‑margin food assets, most recently merging its food arm with McCormick in a $66 billion deal that creates a $20 billion‑revenue business. The twin results underscore a shift toward higher‑margin categories.

Analysts see the bite‑size strategy as a hedge against the emerging threat of prescription weight‑loss drugs, which could erode indulgent ice‑cream demand. By expanding low‑calorie, protein‑rich SKUs, Magnum aims to retain health‑focused consumers without cannibalising its premium image. The approach appears to have steadied the brand’s market share as the sector adjusts to evolving consumer diets.